#BEGIN_DRUGCARD DB00263

# AHFS_Codes:
08:12.20

# ATC_Codes:
J01EB05
S01AB02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Pediazole (Erythromycin (Erythromycin Ethylsuccinate) + Sulfisoxazole Acetyl)
Renazone Plus Tab (Ammonium Chloride + Atropine Sulfate + Hyoscyamine Hydrobromide + Scopolamine Hydrobromide + Sulfisoxazole)

# Brand_Names:
Accuzole
Alphazole
Amidoxal
Astrazolo
Azo Gantrisin
Azosulfizin
Bactesulf
Barazae
Chemouag
Cosoxazole
Dorsulfan
Dorsulfan Warthausen
Entusil
Entusul
G-Sox
Ganda
Gantrisin
Gantrisine
Gantrisona
Gantrosan
Isoxamin
J-Sul
Koro-Sulf
Neazolin
Neoxazol
Norilgan-S
Novazolo
Novosaxazole
Pancid
Renosulfan
Resoxol
Roxosul
Roxosul Tablets
Roxoxol
Saxosozine
Sk-Soxazole
Sodizole
Sosol
Soxamide
Soxazole
Soxisol
Soxitabs
Soxo
Soxomide
Stansin
Sulbio
Sulfagan
Sulfagen
Sulfalar
Sulfapolar
Sulfasan
Sulfasol
Sulfazin
Sulfisin
Sulfizin
Sulfizol
Sulfizole
Sulfoxol
Suloxsol
Sulphafuraz
Sulsoxin
Thiasin
Tl-Azole
Unisulf
Urisoxin
Uritrisin
Urogan
V-Sul
Vagilia

# CAS_Registry_Number:
127-69-5

# ChEBI_ID:
102484

# Chemical_Formula:
C11H13N3O3S

# Chemical_IUPAC_Name:
4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
363774

# Description:
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anti-Infective Agents
Anti-Infectives
Sulfonamides

# Drug_Interactions:
Chlorpropamide	Sulfonamide/sulfonylurea: possible hypoglycemia
Methotrexate	The sulfamide increases the toxicity of methotrexate
Tamoxifen	Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed.
Tolbutamide	Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
Torasemide	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed.
Trimethoprim	The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed.
Voriconazole	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.
Warfarin	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.
Zafirlukast	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.01

# Experimental_Logs:
-2.91

# Experimental_Water_Solubility:
300 mg/L (at 37 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfisoxazole

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3

# InChI_Key:
InChIKey=NHUHCSRWZMLRLA-UHFFFAOYSA-N

# Indication:
For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.

# KEGG_Compound_ID:
C07318

# KEGG_Drug_ID:
D00450

# LIMS_Drug_ID:
263

# Mechanism_Of_Action:
Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

# Melting_Point:
191 °C

# Molecular_Weight_Avg:
267.304

# Molecular_Weight_Mono:
267.067761987

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164748964

# Pharmacology:
Sulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

# Predicted_LogP_Hydrophobicity:
1.14

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
3.13e-01 g/l

# Primary_Accession_No:
DB00263

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5344

# PubChem_Substance_ID:
46505342

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00595

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Sulfadimethylisoxazole
Sulfafurazol
Sulfafurazole
Sulfaisoxazole
Sulfasoxazole
Sulfisonazole
Sulfisoxasole
Sulfisoxazol
Sulfisoxazole Dialamine
Sulfisoxazole Diolamine
Sulfofurazole
Sulphafurazol
Sulphafurazole
Sulphafurazolum
Sulphaisoxazole
Sulphisoxazol
Sulphofurazole

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=6800 mg/kg (Orally in mice)

# Update_Date:
2013-02-08 16:19:13 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sulfisoxazole

# pKa_Isoelectric_Point:
5

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15673729	Fiebelkorn KR, Crawford SA, Jorgensen JH: Mutations in folP associated with elevated sulfonamide MICs for Neisseria meningitidis clinical isolates from five continents. Antimicrob Agents Chemother. 2005 Feb;49(2):536-40.
16000430	Jorgensen JH, Crawford SA, Fiebelkorn KR: Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005 Jul;43(7):3162-71.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
7486915	Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68776

# Drug_Target_1_GenBank_ID_Protein:
41273

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
folP

# Drug_Target_1_Gene_Sequence:
>849 bp
ATGAAACTTTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATC
CTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCG
GTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAG
TCCACGCGCCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCT
GTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCAGTCGATACATCCAAACCA
GAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAATGATATCCGCTCCCTT
TCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCAT
ATGCAGGGAAATCCAAAAACCATGCAGGAAGCTCCGAAGTATGACGATGTCTTTGCAGAA
GTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAG
AAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTA
CTGGCGCGCCTGGCTGAATTTCACCATTTCAACCTGCCGCTGTTGGTGGGTATGTCACGA
AAATCGATGATTGGGCAGCTGCTGAACGTGGGGCCGTCCGAGCGCCTGAGCGGTAGTCTG
GCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATCATTCGTGTTCATGACGTCAAA
GAAACCGTAGAAGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGAAAACAAACGC
TATGAGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1522070	Dallas WS, Gowen JE, Ray PH, Cox MJ, Dev IK: Cloning, sequencing, and enhanced expression of the dihydropteroate synthase gene of Escherichia coli MC4100. J Bacteriol. 1992 Sep;174(18):5961-70.
1657875	Talarico TL, Dev IK, Dallas WS, Ferone R, Ray PH: Purification and partial characterization of 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase and 7,8-dihydropteroate synthase from Escherichia coli MC4100. J Bacteriol. 1991 Nov;173(21):7029-32.
8304179	Swedberg G, Fermer C, Skold O: Point mutations in the dihydropteroate synthase gene causing sulfonamide resistance. Adv Exp Med Biol. 1993;338:555-8.
9187658	Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK: Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol. 1997 Jun;4(6):490-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
891

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30616

# Drug_Target_1_Name:
Dihydropteroate synthase

# Drug_Target_1_Number_of_Residues:
282

# Drug_Target_1_PDB_ID:
1AJZ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthase
MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGE
STRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSL
SEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKE
KLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSL
ACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide

# Drug_Target_1_SwissProt_ID:
P0AC13

# Drug_Target_1_SwissProt_Name:
DHPS_ECOLI

# Drug_Target_1_Synonyms:
DHPS
Dihydropteroate pyrophosphorylase
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00263
